ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
29/01/2020
Voltar para busca
Dado oficial do USPTO
ALLPHASE CLINICAL RESEARCH
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
29/01/2020
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
35, 39, 41, 42
Data de depósito
22/08/2006
Data de registro
12/08/2008
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
21/08/2018
Última transação
21/08/2018
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Primeiro uso
05/01/2001
Primeiro uso no comércio
2003-04-00
Código do desenho
3
Tipo de titular
11
Localização do titular
OTTAWA, ON
Examinador
PINO, BRIAN
Unidade examinadora
M50
Localização atual
GENERIC WEB UPDATE
Descrição da marca
The mark consists of a stylized leaf above the word "ALLPHASE CLINICAL RESEARCH".
Titulares e representantes
Titulares
ALLPHASE CLINICAL RESEARCH SERVICES INC.
Allphase Clinical Research (US), Inc.
Representantes
Mary Margaret L. O'Donnell Blue Filament Law PLLC
Classificação técnica
Classes Nice
Classe 35Classe 39Classe 41Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 35
Pre-clinical to phase four clinical trial management servicespre-study document collection and reviewsite selectionvisits and auditssite complianceproject tracking and monitoring reportsnegotiation and administration of investigator grantslabelingpackagingdistributioncoordination and tracking of clinical trial products and materialsregulatory document processingcentral laboratory selection and coordination; pre-clinical to phase four clinical trial management servicesmanaging site and study-specific subject recruitment strategies and programs in the nature of contingency strategies and solutions to address specific project challenges; pre-clinical to phase four clinical trial management servicesmanaging the development of all study related documents and materials in the nature of study protocolsamendmentspaper and electronic case report formsinformed consent formsdiary cardssafety narrativespresentation posterstechnical briefs and training manuals; pre-clinical to phase four clinical trial management servicesmanaging all aspects of studydrug reconciliationinventory and distribution reportsmanaging all aspects of clinical trialsmanaging investigatorstechniciansparticipantsethical reviewsinvestigator meetingsdatabasesstatistical analyses and reportingrandomization logisticsmedical writing servicesrecruitment of investigatorstechnicians and participants; providing data management services in the medicalpharmaceutical and biotechnological field
Classe 39
Clinical supply storage in the field of clinical and medical supplies
Classe 41
Providing training in the field of clinical trials and clinical trial management for the pharmaceutical and biotechnological industries
Classe 42
Medical and scientific research consulting regarding pre-clinical to phase four clinical trials; regulatory affairsreviewing standards and practices to assure compliance with clinical trial laws and regulations; providing quality assurance services in the pharmaceutical and biotechnological industries
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
21/08/2018
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
21/08/2018
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
21/08/2018
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
21/08/2018
E89R
TEAS SECTION 8 & 9 RECEIVED
10/08/2018
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
12/08/2017
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
25/05/2017
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
23/08/2014
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
23/08/2014
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
23/08/2014
E815
TEAS SECTION 8 & 15 RECEIVED
08/08/2014
R.PR
REGISTERED-PRINCIPAL REGISTER
12/08/2008
REGV
LAW OFFICE REGISTRATION REVIEW COMPLETED
08/07/2008
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/07/2008
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/06/2008
IUAF
USE AMENDMENT FILED
06/06/2008
EISU
TEAS STATEMENT OF USE RECEIVED
06/06/2008
NOAM
NOA MAILED - SOU REQUIRED FROM APPLICANT
05/02/2008
PUBO
PUBLISHED FOR OPPOSITION
13/11/2007
NPUB
NOTICE OF PUBLICATION
24/10/2007
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
07/10/2007
ALIE
ASSIGNED TO LIE
07/10/2007
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/09/2007
XAEC
EXAMINER'S AMENDMENT ENTERED
06/09/2007
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/09/2007
GNEA
EXAMINERS AMENDMENT E-MAILED
06/09/2007
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/09/2007
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
23/07/2007
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
23/07/2007
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/07/2007
GNRT
NON-FINAL ACTION E-MAILED
23/01/2007
CNRT
NON-FINAL ACTION WRITTEN
23/01/2007
DOCK
ASSIGNED TO EXAMINER
17/01/2007
MDSM
NOTICE OF DESIGN SEARCH CODE MAILED
29/08/2006
NWAP
NEW APPLICATION ENTERED
28/08/2006
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ALLPHASE CLINICAL RESEARCH ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.